DelveInsight's Mismatch Repair Deficiency Market Insights report includes a comprehensive understanding of current treatment practices, mismatch repair deficiency emerging drugs, market share of ...

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...

NG-350A has received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial ...

The ultimate recommendation is to utilize immune checkpoint blockade in the front-line setting, even for pMMR patients. This ...

Deficiencies in DNA mismatch repair have been associated with inferior response to 5-FU in colorectal cancer. Pancreatic ductal adenocarcinoma is similarly treated with pyrimidine analogs, yet the ...

Prof David Kerr discusses a recent study investigating tumor mutational burden as a potential contributing factor to ...

Mismatch repair protein immunohistochemistry is a widely used method for detecting patients at risk for Lynch syndrome. Recent data suggest that a two-antibody panel approach using PMS2 and MSH6 is an ...

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg ...